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Anti-IL-10 Therapeutic Strategy Using the Immunomodulator
AS101 in Protecting Mice from Sepsis-Induced Death:
Dependence on Timing of Immunomodulating Intervention1
Yona Kalechman,* Uzi Gafter,† Rivka Gal,† Galit Rushkin,* Donghong Yan,* Michael Albeck,‡
and Benjamin Sredni2*
The role of IL-10 in experimental sepsis is controversial. The nontoxic immunomodulator, ammonium trichloro(dioxoethylene-
o,o)tellurate (AS101) has been previously shown to inhibit IL-10 expression at the transcriptional level. In this study, we show that
in mice subjected to cecal ligation and puncture (CLP), treatment with AS101 12 h after, but not before, CLP significantly
increased survival of septic mice. This was associated with a significant decrease in serum IL-10 and in IL-10 secretion by
peritoneal macrophages 24–48 h after CLP. At that time, the ability of these cells to secrete TNF- and IL-1 was restored in
AS101-treated mice. The increased survival of AS101-treated mice was due to the inhibition of IL-10, since cotreatment with
murine rIL-10 abolished the protective activity of AS101. AS101 increased class II Ag expression on peritoneal macrophages,
severely depressed in control mice, while it did not affect the expression of class I Ags. This was accompanied by a significant
elevation in the level of IFN- secreted by splenocytes. Moreover, AS101 ameliorated bacterial clearance in the peritoneum and
blood and decreased severe multiple organ damage, as indicated by clinical chemistry. Furthermore, myeloperoxidase levels in the
liver and lung of AS101-treated mice, an indirect means of determining the recruitment of neutrophils, were significantly de-
creased. We suggest that nontoxic agents such as AS101, with the capacity to inhibit IL-10 and stimulate macrophage functions,
may have clinical potential in the treatment of sepsis, provided they are administered during the phase of sepsis characterized by
immune suppression. The Journal of Immunology, 2002, 169: 384–392.
S epsis syndrome is an acute systemic response to a varietyof noxious insults, particularly bacterial infection. Thissyndrome is accompanied by immunologic processes that
are activated and regulated. The development of immunomodula-
tory therapeutic approaches is therefore one of the principal areas
emphasized in developing modern forms of treatment for sepsis.
The role of cytokines in the pathogenesis of sepsis is complex,
since both deficient and excessive immune responses have been
associated with this syndrome (1). In models of severe systemic
infection or inflammation produced by i.v. administration of high
doses of bacteria or bacterial products such as endotoxin, excessive
production of proinflammatory cytokines significantly contributes
to organ failure and death, as reflected by findings that neutraliza-
tion of either TNF or IL-1 activity markedly reduced mortality in
these systemic challenge models (2, 3). However, in experiments
in which an initially localized infection was induced, including
pneumonia and peritonitis, the local activity of proinflammatory
cytokines appeared important for antibacterial host defense at the
site of infection (4–6). Together these data suggest that proinflam-
matory cytokines are, on the one hand, required locally for effec-
tive antibacterial effector mechanisms, but are, in contrast, poten-
tially toxic when secreted into the circulation. Similarly, several
animal studies indicated an important role for IL-10, the prototyp-
ical antiinflammatory cytokine, in the pathogenesis of bacterial
infection. The administration of neutralizing anti-IL-10 Abs in-
creases endotoxin-induced mortality in mice, while the exogenous
application of IL-10 can prevent septic shock in mice by inhibiting
the synthesis of TNF-, IL-1, IFN-, and other proinflammatory
mediators (7, 8). IL-10 gene-deficient mice demonstrated multiple
organ failure and an enhanced mortality after endotoxin injection
or during Escherichia coli peritonitis (9, 10), despite accelerated
bacterial clearance (10). Nevertheless, during murine pneumonia,
treatment with anti-IL-10 Abs inhibited bacterial outgrowth in
lungs and improved survival (11, 12). However, during septic peri-
tonitis induced by cecal ligation and puncture (CLP),3 neutralizing
IL-10 was associated with an increased mortality (13, 14). In these
experimental systems in which IL-10 or anti-IL-10 Abs were ad-
ministered, the protective or detrimental effects were induced only
if the treatments were applied shortly before or immediately after
LPS, CLP, or bacterial challenge. On the basis of these obser-
vations, a strategy for inhibiting the synthesis of proinflamma-
tory cytokines was developed in an attempt to treat septic pa-
tients. At present, it appears that this approach has not met with
the expected successes. Sepsis-induced mortality was not sig-
nificantly improved in any of the phase II/III studies that have
been completed (15, 16).
Recent studies demonstrated that systemic levels of both the
proinflammatory cytokines and IL-10 are correlated directly with
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severity of illness (17). Several investigations on human infections
indicated that elevated IL-10 predicts a poor prognosis in the pres-
ence of sepsis (18, 19). Recent data of Song et al. (20) suggest that
at later time points after the onset of infection, IL-10 may have a
net detrimental effect on host antimicrobial clearance mechanisms.
In a cecal ligation model, anti-IL-10 Ab delivered at the time of
CLP was ineffective in preventing mortality. However, when ad-
ministered 12 h after CLP, this treatment was protective (20).
These data indicate the critical importance of timing of manipu-
lations that affect IL-10 activity in sepsis.
A biphasic immunologic response in sepsis has been recently
demonstrated: an initial hyperinflammatory phase, followed by a
hypoinflammatory one. The latter stage is associated with an im-
munodeficient stage, which is characterized by monocyte deacti-
vation (21). In this state, monocytic TNF secretion capacity as well
as HLA-DR Ag expression and Ag-presenting capacity are all se-
verely depressed, while, at least temporarily, the capacity to pro-
duce IL-10 is preserved. This switch to predominant release of
antiinflammatory mediators is associated with a high risk of fatal
outcome.
The nontoxic immunomodulator ammonium trichloro(dioxoeth-
ylene-o,o)tellurate (AS101) first developed by us has been shown
to have beneficial effects in diverse preclinical and clinical studies.
Most of its activities have been primarily attributed to the direct
inhibition of the antiinflammatory cytokine IL-10, followed by the
simultaneous increase of specific cytokines. These include IL-1,
TNF-, IFN-, IL-2, IL-12, and GM-CSF (22–24). These immu-
nomodulatory properties were found to be crucial for the clinical
activities of AS101, demonstrating the protective effects of AS101
in parasite- and viral-infected mice models (25), in autoimmune
diseases (26), and in a variety of tumor models in which AS101
had a clear antitumoral effect (27–29). AS101 has also been shown
to have protective properties against lethal and sublethal effects of
irradiation and chemotherapy (24, 27–31). These activities were
also due to the increased production of proinflammatory cytokines
and were associated with only minimal toxicity, thus enabling the
use of the compound as an adjuvant to chemotherapy in phase II
studies (32).
Given the ability of AS101 to decrease monocytic IL-10 pro-
duction (23) and thereby stimulate the production of monocyte-
activating cytokines, increase monocyte B-7 expression, followed
by amelioration of Ag-presenting capacity (33), we examined its
potential role in protecting mice from the lethal effects of sepsis.
For this purpose, we used the model of CLP, which resembles the
clinical syndrome of septic peritonitis, with spillage of polymicro-




Male and female BALB/c mice were bred at Bar Ilan University from
strains obtained from The Jackson Laboratory (Bar Harbor, ME). Two-
month-old male mice were used for experiments.
Animal experiments were performed in accordance with approved in-
stitutional protocols and approved by the Institutional Animal Care and
Use Committee.
AS101
AS101 was supplied by M. Albeck from the chemistry department in Bar
Ilan University, in a solution of PBS, pH 7.4, and maintained at 4°C.
Before use, AS101 was diluted in PBS, and the appropriate concentrations
in 0.2 ml vol were administered to mice by i.p. injections.
Cecal ligation and puncture
Animals were anesthetized using sodium pentobarbital (40 mg/kg) admin-
istered i.p. CLP was performed by making a midline incision 2.5 cm in
length to expose the cecum. A 3-0 silk ligature was placed at the base of
the cecum without causing bowel obstruction. The cecum was then punc-
tured twice with a 21-gauge needle. The cecum was gently squeezed to
assure patency of the two holes as well as to express fecal material into the
peritoneal cavity. In the control animals (sham), the cecum was located, but
neither ligated nor punctured. The abdominal incision was then closed in
two layers using 3-0 Prolene and 4-0 Dexon, respectively. All animals were
fluid resuscitated with 1 ml normal saline by s.c. injection.
IL-10 and anti-IL-10 Abs
Murine rIL-10 (rmIL-10; BD PharMingen, San Diego, CA) was injected
s.c. at 5 g/injection once daily starting 12 h following CLP. Anti-IL-10
(JESS 2A5; BD PharMingen)-neutralizing Abs were injected i.p. at 250
g/mouse at 12 h post-CLP. Rat anti-mouse IgG1 served as control Abs.
Treatment regimen
For survival experiments, PBS or AS101 were injected i.p. daily at various
concentrations starting either 24 h before or at 7 or 12 h following CLP
until the end of experiment. For serum cytokine evaluation, AS101 at 10
g/mouse or PBS was injected once 12 h following CLP.
Cell purification
Spleens were removed and placed in PBS. Spleen cells were passed
through stainless steel mesh nets, treated with hypotonic solution to lyse
erythrocytes, and washed three times. Cell counts were obtained using a
hemocytometer. Viability, as assessed by trypan blue exclusion method,
was always found to be 95%.
Adherent splenocytes were obtained following adherence of cells for 1 h
in plastic dishes in RPMI 1640 culture medium supplemented with
10% FCS.
Peritoneal macrophages were obtained by peritoneal washing with PBS
and adherence of cells for 1 h.
Induction of cytokine secretion in vitro
Splenocytes (5  106/ml) were suspended in enriched RPMI 1640 culture
medium supplemented with 10% FCS and seeded in 24-well culture plates
in the presence of 2.5 g/ml Con A (for IFN-). Adherent splenocytes or
peritoneal macrophages were incubated with 1 g/ml LPS (for IL-1, IL-
10, and TNF-). The cultures were incubated at 37°C for 24 h. Superna-
tants were collected and evaluated for cytokine content.
Quantitation of cytokine levels
The R&D Systems (Minneapolis, MN) IL-1, TNF-, IL-10, and IFN-
ELISA kits were used for the quantitative measurement of these cytokines
either in mice sera or in spleen and peritoneal exudate cell (PEC)
supernatants.
Immunofluorescence staining
Peritoneal cells were incubated with FITC and PE directly labeled Abs
against MHC molecules on ice for 60 min and then washed. The mAbs
used included FITC-labeled mouse IgG2a anti-mouse H-2Dd, rat IgG2a
anti-mouse I-Ad/I-Ed, rat IgG2a anti-mouse I-Ad, and PE-labeled rat IgG1
anti-mouse CD14 (BD PharMingen); purified rat IgG2 Abs (Genzyme,
Cambridge, MA) were used as isotype controls. For each sample, 104 cells
were analyzed on a FACScan (BD Biosciences, Mountain View, CA) eval-
uating the percentage of double-stained CD14 and class I- or class II-
positive cells.
Determination of bacterial CFU in the CLP model
Mice were killed 24 h following CLP. The peritoneal cavities were washed
with 2 ml sterile PBS, and the lavage fluids were harvested under sterile
conditions. A total of 10 l peritoneal lavage fluids and peripheral blood
from each mouse was placed on ice and serially diluted with sterile PBS.
A total of 10 l of each dilution was asceptically plated on tryptose soy
agar blood agar plates (Difco, Detroit, MI) and incubated overnight at
37°C, after which the number of colonies was counted. Data were ex-
pressed as CFU per microliter.
Clinical chemistry
Serum levels of aspartate transaminase (AST), alanine transaminase
(ALT), amylase, blood urea nitrogen (BUN), and creatinine were measured
using standardized techniques.
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Measurement of myeloperoxidase
Myeloperoxidase (MPO) in tissue extracts was measured by ELISA kit
(Calbiochem-Novabiochem, La Jolla, CA), according to the manufactur-
er’s instructions.
Preparation of organ extracts
A total of 0.1 g excised organs was placed in 1 ml PBS containing complete
protease inhibitors (Calbiochem) and homogenized. The homogenates
were subsequently freeze-thawed twice. The homogenates were centri-
fuged at 6000  g for 20 min at 4°C, and the cleared supernatants were
used for measurement of MPO. The levels of MPO in organ extracts were
expressed as ng/mg protein.
Statistical analysis
Survival curves were statistically analyzed by comparing the cumulative
percentage of survival using the Gehan-Wilcoxon test. For comparisons of
means of the various groups, the pairwise t test was used.
Results
Enhanced survival of AS101-treated mice following induction of
sepsis
We first determined whether AS101 may rescue mice from sepsis-
induced death. Peritonitis induced by CLP with a 21-gauge needle
results in 100% lethality at day 9 (Fig. 1). Treatment with AS101
had a salutary effect only if injected after sepsis induction (Fig.
1A). The optimal dose of AS101 was 10 g/mouse, injected 12 h
following CLP and thereafter every day until the end of experi-
ments (Fig. 1). Under these conditions, 60% of treated mice sur-
vived ( p  0.01; increase vs CLP  PBS). This concentration of
AS101 was previously found by us to be optimal in various pre-
clinical studies in which AS101 had beneficial effects. A concen-
tration of 30 g/mouse AS101 was less effective, although this
dose also significantly increased the rate of survival ( p  0.05). A
lower concentration of 5 g/mouse was ineffective (Fig. 1B). In-
jection of AS101 7 h post-CLP was also effective, although to a
lesser extent (20%; p  0.05). No significant difference was ob-
served when AS101 was injected at the time of injury (time zero).
Notably, treatment with AS101 24 h before CLP decreased sur-
vival, compared with PBS-treated mice. Thus, it appears that
AS101 could protect mice from sepsis-induced death only if in-
jected after, but not before, or at the time of sepsis induction.
Plasma levels of cytokines
Organ injury observed in sepsis is due to the explosive release of
cytokines into the plasma. We therefore sought to determine the
plasma levels of cytokines folowing CLP and their response to
AS101 treatment. Two of the classic cytokines produced in the
initial period of an inflammatory insult are TNF- and IL-1,
which are followed by overproduction of IL-10. It can be seen that
TNF- and IL-1 were undetectable in the serum at 1 h post-CLP
(Fig. 2). Maximal levels of these cytokines were found at 6 and
12 h. The inflammatory response was not persistent and it gradu-
ally declined, until at 24–48 h after CLP it was only minimal.
Evaluation of plasma levels of proinflammatory cytokines in the
AS101-treated mice revealed no significant differences in plasma
TNF- and IL-1 levels between AS101- and PBS-treated mice
(Fig. 2).
Since every inflammatory response stimulates not only the syn-
thesis of proinflammatory mediators, but also, with a slight delay,
the production and secretion of antiinflammatory cytokines such as
IL-10, we chose to evaluate the concentrations of this cytokine in
the plasma of sepsis-induced mice. Moreover, we determined
whether AS101 can inhibit the production of this cytokine.
Quantitation of IL-10 plasma levels revealed a gradual increase
in plasma content of this antiinflammatory cytokine that peaked at
24 h following CLP. These levels remained elevated until 96 h
after CLP (Fig. 3), although they gradually decreased (data not
shown). AS101 injected 12 h after CLP promptly and significantly
( p  0.01) inhibited IL-10 levels at both 24 and 48 h (Fig. 3). At
72–96 h, IL-10 levels in the AS101 group were negligible (data not
shown).
Role of IL-10 inhibition in the increased survival of AS101-
treated mice
The primary effect of AS101 has been shown previously to involve
the direct inhibition of IL-10 in human and mouse macrophages, at
the transcription level (23). Moreover, most of the beneficial ac-
tivities of AS101 observed in preclinical studies have been pri-
marily attributed to the direct inhibition of IL-10 (25–27). We
therefore examined the role of IL-10 inhibition in the increased
survival of AS101-treated mice subjected to CLP. To this end, we
injected AS101-treated mice with rmIL-10 (5 g/injection) once
daily starting 12 h after the induction of CLP. Fig. 4 shows that
treatment with rmIL-10 significantly reduced the salutary effect of
AS101. The percentage of survival decreased from 60 to 10%
( p  0.01). Treatment of PBS-treated mice with rmIL-10 starting
12 h following CLP resulted in enhanced mortality, 100% of mice
FIGURE 1. Enhanced survival of AS101-treated mice following induc-
tion of sepsis. AS101 at 10 g/injection/mouse or PBS were injected to
mice at various time points before and after CLP (A); AS101 at various
doses or PBS were injected 12 h after CLP (B) and thereafter once daily
until the end of experiments. Survival was monitored for 9 days. Results
shown represent a total of 30 mice/group. , p  0.01 increase vs PBS; ,
p  0.05 increase vs PBS.
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dying 7 days following CLP. Alternatively, injection of neutraliz-
ing anti-IL-10 Abs 12 h after CLP resulted in 50% survival ( p 
0.01 vs control Ab).
Prevention of macrophage deactivation
Recently, it has been suggested that septic patients demonstrate a
state in which monocytic TNF secretion capacity as well as
HLA-DR Ag expression are severely depressed, while the capacity
to produce IL-10 is at least temporarily preserved (35). This pre-
dominantly antiinflammatory state, in contrast to the assumption of
persistent hyperinflammation, was associated with a high risk of
death from persistent infection and multiple organ failure.
Table I shows that peritoneal macrophages obtained from CLP-
induced mice gradually lose the ability to secrete TNF- and IL-
1. This loss of function is significantly reflected at 24–48 h fol-
lowing CLP. At 48 h, peritoneal macrophages completely lose
their ability to secrete those proinflammatory cytokines (Table I).
This capacity is significantly restored ( p  0.01) in AS101-treated
mice at all time points following AS101 injections. Similar results
were obtained when TNF- and IL-1 in supernatants from ad-
herent splenocytes were quantitated (data not shown). In contrast
to the loss of macrophage ability to secrete TNF- and IL-1, the
capacity of PEC cells to secrete IL-10 at 24–48 h was preserved.
Nevertheless, PEC cells from AS101-treated mice secreted signif-
icantly decreased amounts of IL-10 at 24–48 h post-CLP ( p 
0.01) (Table I).
FIGURE 3. Kinetics of serum IL-10 levels after CLP. AS101 at 10 g/
injection or PBS was injected into mice 12 h after CLP. Serum IL-10 levels
were quantitated at different time points after CLP. The results represent
means  SE of three experiments including 18 mice/group. , p  0.01
decrease vs PBS.
FIGURE 4. AS101 enhances survival of sepsis-induced mice by inhi-
bition of IL-10. AS101 at 10 g/injection/mouse or PBS was injected into
mice 12 h after CLP with or without 5 g rmIL-10 and thereafter once
daily until the end of experiments. One group was injected with PBS and
neutralizing anti-IL-10 Abs. Rat anti-mouse IgG1 served as control Abs.
Survival was monitored for 9 days. Results represent a total of 10 mice/
group. , p  0.01 increase vs control Ab; , p  0.01 decrease vs AS101.
Table I. Kinetics of cytokine secretion from PEC cells after CLPa
Hours after
CLP TNF- (pg/ml) IL-1 (pg/ml) IL-10 (pg/ml)
PBS 0 4368  396 6166  512 236  26
PBS 12 4653  502 6645  624 221  26
PBS 24 1523b  142 1546b  148 187c  20
AS101 24 3266d  219 4286d  386 121e  10
PBS 48 46b  5 86b  10 182c  16
AS101 48 1984d  160 2018d  194 126e  13
a AS101 at 10 g/injection/mouse or PBS were injected into mice 12 h after CLP.
At various time points, PEC cells were harvested and cultured with LPS. Supernatants
were quantitated for TNF-, IL-1, and IL-10 content. The results represent means 
SE of three experiments including 18 mice/group.
b p  0.01.
c p  0.05, decrease vs time zero.
d p  0.01, increase vs PBS.
e p  0.01, decrease vs PBS.
FIGURE 2. Kinetics of serum TNF- (A) and IL-1 (B) levels after
CLP. AS101 at 10 g or PBS was injected into mice 12 h after CLP. Serum
TNF- and IL-1 levels were quantitated at different time points after
CLP. The results represent means  SE of three experiments including 18
mice/group. , p  0.01 increase vs time 0 and 3 h.
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To evaluate the depressed class II monocyte Ag expression, the
proportion of both CD14I-A and CD14I-A/I-E cells was de-
termined at different time points following CLP. As can be seen in
Fig. 5A, the proportion of CD14 peritoneal cells expressing I-A
Ag gradually decreased following CLP from 26.2  2 to 4  2%
at 48 h post-CLP. Administration of AS101 12 h after CLP sig-
nificantly restored the percentage of I-A-expressing CD14
cells. This was reflected by an increase amounting to 17  1%
CD14I-A cells at 24 h post-CLP and 23  2% CD14I-A
cells at 48 h after the insult. Similar results were obtained when the
proportion of CD14 cells expressing both I-A and I-E was eval-
uated. While the percentage of these cells decreased from 61  5%
to 6  1% at 48 h post-CLP, they amounted at that time point to
55  6% in mice treated with AS101 (Fig. 5B).
No differences in the expression of class I Ags on CD14 cells
were observed at various time points after CLP induction (Fig. 5c).
Treatment with AS101 did not alter H-2D Ag expression on
CD14 cells.
Effect of AS101 on IFN- production by spleen cells
The increased expression of class II Ags on CD14 cells from
AS101-treated mice led us to examine the level of IFN- produc-
tion and secretion in these mice due to the potent ability of this
cytokine to induce class II Ag expression on CD14 cells. As can
be seen in Fig. 6, Con A-stimulated splenocytes significantly de-
crease their ability to secrete IFN- at 24–48 h following CLP. A
considerable and significant increase ( p  0.01) in the levels of
FIGURE 6. Treatment with AS101 increases the ability of splenocytes
from mice after CLP to secrete IFN-. AS101 at 10 g/injection/mouse or
PBS was injected in mice 12 h after CLP. At various time points, spleno-
cytes were harvested and cultured with Con A. Supernatants were quanti-
tated for IFN- content. The results represent means  SE of three exper-
iments including 18 mice/group. , p  0.01 increase vs PBS.
FIGURE 7. AS101 increases the clearance of bacteria after CLP.
AS101 at 10 g or PBS was injected in mice 12 h after CLP. At 24 h after
CLP, mice were killed and the peritoneal fluids and sera were harvested. A
total of 10 l peritoneal fluids and sera was serially diluted and plated on
tryptose soy agar blood agar plates. The results represent 10 AS101-treated
and 9 PBS-treated mice. Line represents mean CFU count.
FIGURE 5. Treatment with AS101 increases the expression of class II
and not class I Ag expression in PEC cells from mice after CLP. AS101 at
10 g/injection/mouse or PBS was injected in mice 12 h after CLP. The
percentage of CD14 cells expressing class II Ags (I-A, A; or I-A/I-E, B)
or class I Ags (H-2D, C) was determined at various time points after CLP.
The results represent means  SE of three experiments including 18 mice/
group. , p  0.01 increase vs PBS.
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IFN- were obtained at all time points following AS101 injections
when splenocytes from AS101-treated mice were used (Fig. 6).
Augmentation of bacterial clearance in AS101-treated mice
IL-10 has been shown recently to impair bacterial clearance from
the peritoneal cavity and to facilitate dissemination of bacteria to
distant organs (10). The significant decrease in serum IL-10 levels
in CLP-induced mice treated with AS101, as well as the increased
survival of these mice led us to evaluate the role of AS101 in the
bacterial clearance of mice subjected to CLP. To this end, we
examined the bacterial load in the peritoneal fluids and blood of
AS101- and PBS-treated mice. No bacteria were recovered from
the peritoneum or blood of mice that were not subjected to CLP
(data not shown). The peritoneal fluids at 24 h after CLP in PBS-
injected mice contained a significant number of bacteria in the
peritoneum (Fig. 7). At this time point, the bacterial load in the
peritoneum of AS101-treated mice was significantly decreased
( p  0.01). At 72 h, AS101-treated mice who shivered and had
bristled hair, clinical symptoms of active sepsis, had increased
peritoneal bacterial load (13,000–40,000 CFU/10 l). These
amounted to 40%. In the remaining mice, the peritoneal bacterial
load did not change significantly as compared with that at 24 h
after CLP (data not shown). Likewise, the bacterial load recovered
from peripheral blood of AS101-treated mice was significantly
lower than that in control PBS-treated mice ( p  0.05) (Fig. 7).
CLP-induced organ injury is ameliorated in AS101-treated mice
Sepsis frequently causes multiple organ failure, a condition that
leads to death (36). To understand the mechanism whereby
AS101-treated mice were resistant to CLP, experiments were con-
ducted to assess the organ damage induced by CLP and its re-
sponse to AS101. For this purpose, we measured biochemical
markers of liver damage (AST, ALT), pancreas damage (amylase),
and renal failure (creatinine, BUN) at 24 h following CLP. Fig. 8
shows that control PBS-treated mice demonstrated biochemical
evidence of more severe multiple organ damage than AS101-
treated mice, as reflected by higher ALT, AST, amylase, creati-
nine, and BUN concentrations (all p  0.05). The levels in AS101-
treated mice were comparable with those in mice not subjected to
CLP, suggesting that organ injury was avoided in AS101-treated
mice. Nevertheless, in 40% of mice in the AS101 group, in which
the bacterial load was elevated at 72 h, the levels of AST and ALT
increased to 100–120 U/L and 65–80 U/L, respectively, at that
time (data not shown), suggesting that in these mice organ damage
was only delayed and not entirely avoided.
Evaluation of MPO levels in infected organs
MPO level is an indirect means of determining the recruitment of
neutrophils to the infected organs. As can be seen in Fig. 9, MPO
levels in the liver and lung, 24 h after CLP, were elevated in
PBS-treated mice as compared with AS101-treated mice. This in-
crease was significant in both organs ( p  0.01; p  0.05). The
level of MPO in both organs in control PBS-treated mice was
10-fold increased as compared with normal untreated mice.
MPO levels in the kidney of PBS-treated mice were only slightly
elevated as compared with untreated mice (2-fold). AS101 also
decreased the level of MPO in the kidney, but not significantly
(Fig. 9).
Discussion
In the present study, we present evidence demonstrating the ability
of AS101 to protect from sepsis-induced death. This protection
was observed provided AS101 was injected after, and not during
the initial hyperinflammatory state induced by CLP. Moreover, we
show that the increased survival of AS101-treated mice subjected
to CLP is due, mostly, to the prompt inhibition of the antiinflam-
matory cytokine IL-10. As shown in this study, the initial period
following the inflammatory insult was characterized by a hyper-
inflammatory response, as reflected by high serum levels of TNF-
and IL-1, 6 h after CLP. Nevertheless, the proinflammatory re-
sponse was not consistent and it gradually decreased over 24–48
h. This was followed by an immune suppressed state characterized
by overproduction of IL-10. Treatment with AS101 12 h following
CLP did not result in important changes in serum TNF- or IL-1
FIGURE 8. Treatment with AS101 ameliorates organ injury induced by CLP. AS101 at 10 g/injection/mouse or PBS was injected into mice 12 h after
CLP. At 24 h after CLP, mice were killed, and the amounts of AST, ALT, BUN, creatinine, and amylase in sera were measured. The results represent
means  SE of 10 mice/group. Line represents mean data obtained from sham-operated mice (n  4). ; p  0.05 decrease vs PBS.
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levels. However, the antiinflammatory response was profoundly
decreased in AS101-treated mice, as reflected by profound sup-
pression of serum IL-10 levels. The switch to an antiinflammatory
state in late sepsis was also reflected by the relatively preserved
ability of peritoneal macrophages from untreated CLP-induced
mice to secrete IL-10, while their ability to secrete TNF- and
IL-1 was totally lost. Treatment of mice with AS101 decreased
IL-10 secretion by macrophages and restored their ability to pro-
duce and secrete proinflammatory cytokines.
AS101 has previously been shown to directly inhibit IL-10 pro-
duction by both mice and human macrophages, at the transcrip-
tional level (23). This property accounted for most of the beneficial
effects of AS101 in preclinical studies associated with IL-10
overexpression.
In some of those models, such as systemic lupus erythematosus,
the beneficial effect of AS101 was directly due to the inhibition of
the high levels of IL-10, resulting in decreased production of au-
toantibodies and delayed development of lupus-like autoimmunity
(26). In other models such as tumor-bearing (27) or parasite- and
viral-infected mice (25), the salutary effect of AS101 was due to its
ability to switch predominant type II responses to type I responses,
thus augmenting the cell-mediated immune response to cancer,
viral, and parasitic infections. Moreover, inhibition by AS101 of
IL-10 production by macrophages results in up-regulation of the
costimulatory molecule B7-1, and increased Ag-presenting ability
of these cells (33). Most importantly, AS101 decreases IL-10 pro-
duction only in models associated with overproduction of this cy-
tokine, resulting in nearly normal IL-10 levels, followed by in-
creased, yet normal, levels of proinflammatory and Th1 cytokines.
This probably accounts for AS101’s lack of toxicity, enabling the
use of the compound as an adjuvant to chemotherapy in phase II
studies (32).
The cytokine network plays a pivotal role in the orchestration of
inflammatory responses to bacterial infection. The balance be-
tween pro- and anti-inflammatory cytokines critically influences
the function of immunocompetent cells and the resistance against
infection. While proinflammatory cytokines such as IL-12 and
TNF- have been shown to enhance bacterial clearance in several
bacterial infection models including septic peritonitis (37, 38), an-
tiinflammatory cytokines such as IL-10 and IL-13 have been
shown to play a protective role in this model of sepsis, by down-
regulating the excessive inflammatory response (13, 39), while
IL-10 was not successful as a therapeutic strategy in a cecal liga-
tion model of intraabdominal sepsis (40). The development of an
adequate immune response to a bacterial challenge relies on the
complex interplay between the inate and the specific immune sys-
tem, reflected by intact monocyte/T cell/neutrophil interactions.
Monocyte and macrophage functions include the recognition, up-
take, and killing of invading organisms, and Ag presentation to
initiate an immune response. The early stages of such a response
may be mediated by secretion of proinflammatory mediators such
as TNF, IL-1, IL-12, and a direct Ag-presenting capacity reflected
by the expression of HLA class II and CD80/86. These monocyte
functions are up-regulated by immunostimulatory cytokines such
as IFN- and suppressed by IL-10. This functional monocytic de-
pression is closely associated with a loss of type I T cell response,
which can be characterized by an increase in Th cell production of
IL-4 and IL-10 and a decreased IFN--producing Th cell pheno-
type. Indeed, Song et al. (20) have recently shown that IL-10 is
involved in the immune dysfunction in splenic lymphocytes from
septic animals, as reflected by their decreased ability to release
IL-2 and IFN-. Furthermore, the role of IL-10 in depressing
monocyte functions important in sepsis was recently demonstrated
(41). These data are in line with our results showing that treatment
with AS101, through inhibition of IL-10, restores moncytic func-
tions, as reflected by preservation of their ability to secrete TNF-
and IL-1 and by the prompt increase of their class II Ag expres-
sion. Moreover, treatment with AS101 restores the ability of lym-
phocytes to secrete IFN-, a known up-regulator of monocyte
functions. Taken together, it appears that sepsis is characterized by
a biphasic immunologic response: an initial systemic proinflam-
matory mediator response that is the motor for developing the
anti-inflammatory response causing immune cell dysfunction.
Therefore, a number of investigators have suggested that inhibition
of this proinflammatory response may provide a survival benefit.
However, this often does not take into consideration that the de-
gree of proinflammation produced in response to a polymicrobial
insult, such as CLP, is typically modest compared with that seen in
lethal endotoxemia. A number of studies have documented that the
levels of proinflammatory mediators such as TNF and IL-1 pro-
duced in CLP may actually be required to initiate a protective
immune response and that anti-TNF Ab therapy fails to prevent
lethality after CLP (42, 43).
Our results, demonstrating the beneficial effects of AS101 in
CLP-induced sepsis, illustrate not only the significance of the im-
munosuppressive mediator IL-10 in the development of sepsis, but
also the importance of correct timing of the potential intervention.
Most studies demonstrating the beneficial effect of IL-10 in sepsis
either injected IL-10 before or immediately after the induction of
sepsis, or used IL-10 knockout mice to demonstrate the role of
endogenous IL-10 in sepsis. In the first case, IL-10 was injected in
mice in which an excessive hyperinflammatory state dominated.
Therefore, this treatment balanced hyperinflammation. However,
in IL-10 KO mice, some degree of hyperinflammation exists be-
fore the induction of sepsis. In this case, after the insult, hyperin-
flammation is more excessive than in normal mice subjected to
FIGURE 9. Treatment with AS101 decreases MPO levels in organs after CLP. Twenty-four hours after CLP induction, mice were killed and the liver,
lung, and kidney were resected. The organs were extracted, and the amounts of MPO were measured. The results represent means  SE of 10 mice/group.
Line represents mean data obtained from sham-operated mice (n  4). , p  0.01; , p  0.05 increase vs AS101.
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sepsis. Alternatively, we show in the present study that the re-
sponse of sepsis-induced mice to treatment with an agent that de-
creases IL-10 levels depends on the time of therapeutic interven-
tion. When AS101 was injected before CLP, a significant decrease
in the percentage of survival was obtained. Only when AS101 was
injected at the time in which the anti-inflammatory response pre-
dominated was the resulting decrease in IL-10 beneficial to the
septic mice. Treatment with AS101 at that stage of sepsis eventu-
ally restored the balance between the pro- and antiinflammatory
arms of the cytokine network, ameliorating the bacterial clear-
ance on the one hand and diminishing organ damage in contrast.
AS101 protects 60% of mice from sepsis-induced death. In the
remaining 40%, the level of bacterial load and that of organ
damage is only delayed and is increased later on until the mice
die. These data are in line with studies (20) that showed that
treatment with anti-IL-10 Abs during the immune suppressive
state (12 h after CLP) markedly increased survival. Our data are
also consistent with studies (44) showing that inhibition of mi-
togen-activated protein kinase p38 in vivo results in suppres-
sion of IL-10 and in increased survival, provided the inhibitor
is injected 12 h post-CLP.
Our results may explain why clinical trials with septic patients
aimed at down-regulating proinflammatory cytokines using Abs
against TNF-, antagonists of IL-1, or platelet-derived growth fac-
tor have proved to be uniformly disappointing. Not only have these
agents been found to be ineffective, but they may also increase
mortality. It appears that these trials all addressed the proinflam-
matory phase of sepsis when there was no evidence that the proin-
flammatory phase was dominant.
Taken together, clinical and experimental evidence suggests
that septic patients are not necessarily in an overactivated im-
munological state. Therefore, any immunomodulatory therapy
should be based on measurable immune functions to determine
which patients may benefit from such therapies. We suggest that
the use of the nontoxic compound AS101, currently undergoing
phase II clinical trials, has potential in the clinical treatment of
sepsis if given during the immune suppressive state of septic
patients.
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